Tauns Laboratories Inc
TSE:197A
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
Tauns Laboratories Inc
TSE:197A
|
56.8B JPY |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
60B USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
8.9T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
29.6B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
109.6B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.6B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.8B CNY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
3.9B CHF |
Loading...
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
4.8B USD |
Loading...
|
Market Distribution
| Min | -122 700% |
| 30th Percentile | 2.9% |
| Median | 5.4% |
| 70th Percentile | 8.5% |
| Max | 63 031.4% |
Other Profitability Ratios
Tauns Laboratories Inc
Glance View
TAUNS Laboratories, Inc. develops and manufactures vitro diagnostic drugs & measuring instruments. The company is headquartered in Izunokuni-Shi, Shizuoka-Ken and currently employs 316 full-time employees. The company went IPO on 2024-06-20. The firm operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Tauns Laboratories Inc is 27.3%, which is below its 3-year median of 32%.
Over the last 1 years, Tauns Laboratories Inc’s Net Margin has decreased from 32.3% to 27.3%. During this period, it reached a low of 27.3% on Oct 30, 2025 and a high of 33.9% on Jun 30, 2025.
